Výsledky vyhledávání - "J Elassaiss-Schaap"

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Population Pharmacokinetic/Pharmacodynamic Modeling of Tumor Size Dynamics in Pembrolizumab-Treated Advanced Melanoma

Autor: MS Chatterjee, J Elassaiss-Schaap, A Lindauer, DC Turner, A Sostelly, T Freshwater, K Mayawala, M Ahamadi, JA Stone, R de Greef, AG Kondic, DP de Alwis

Publikováno v: CPT: Pharmacometrics & Systems Pharmacology. 6:29-39

Pembrolizumab is a potent immune-modulating antibody active in advanced melanoma, as demonstrated in the KEYNOTE-001, -002, and -006 studies. Longitudinal tumor size modeling was pursued to quantify exposure-response relationships for efficacy. A mix

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::22f90ad2a352b5aec15b33ce0b21d9c8
https://doi.org/10.1002/psp4.12140

Zobrazit plný text záznamu

Pembrolizumab: Role of Modeling and Simulation in Bringing a Novel Immunotherapy to Patients With Melanoma

Autor: R, de Greef, J, Elassaiss-Schaap, M, Chatterjee, D C, Turner, M, Ahamadi, M, Forman, D, Cutler, D P, de Alwis, A, Kondic, J, Stone

Publikováno v: CPT: Pharmacometrics & Systems Pharmacology

Recently, immunotherapy has yielded promising results in several cancer types. Contrary to the established classical chemotherapy‐dosing paradigm, a maximum tolerated dose approach does not always produce better clinical outcomes for novel targeted

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::8d36883bb68ff64759a6a4d5f73751cf
https://pubmed.ncbi.nlm.nih.gov/27653180

Zobrazit plný text záznamu

Translational Pharmacokinetic/Pharmacodynamic Modeling of Tumor Growth Inhibition Supports Dose-Range Selection of the Anti-PD-1 Antibody Pembrolizumab

Autor: A, Lindauer, C R, Valiathan, K, Mehta, V, Sriram, R, de Greef, J, Elassaiss-Schaap, D P, de Alwis

Publikováno v: CPT: Pharmacometrics & Systems Pharmacology

Pembrolizumab, a humanized monoclonal antibody against programmed death 1 (PD‐1), has a manageable safety profile and robust clinical activity against advanced malignancies. The lowest effective dose for evaluation in further dose‐ranging studies

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::a17fd3512275d9fa8bcb650e110ef26e
https://pubmed.ncbi.nlm.nih.gov/27863176

Zobrazit plný text záznamu

Model-Based Characterization of the Pharmacokinetics of Pembrolizumab: A Humanized Anti-PD-1 Monoclonal Antibody in Advanced Solid Tumors

Autor: M, Ahamadi, T, Freshwater, M, Prohn, C H, Li, D P, de Alwis, R, de Greef, J, Elassaiss-Schaap, A, Kondic, J A, Stone

Publikováno v: CPT: Pharmacometrics & Systems Pharmacology

Pembrolizumab, a potent antibody against programmed death 1 (PD‐1) receptor, has shown robust antitumor activity and manageable safety in patients with advanced solid tumors. Its pharmacokinetic (PK) properties were analyzed with population PK mode

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::8cb1e23ea9fb3fadeb96106d868567e6
https://pubmed.ncbi.nlm.nih.gov/27863186

Zobrazit plný text záznamu

Desmopressin as a pharmacological tool in vasopressinergic hypothalamus-pituitary-adrenal axis modulation: Neuroendocrine, cardiovascular and coagulatory effects

Autor: J. Burggraaf, E.G.J. Hulskotte, J.M.A. van Gerven, Pierre A.M. Peeters, J Elassaiss-Schaap, Lineke Zuurman, ML de Kam, Gé S.F. Ruigt, J. van Pelt, Bernard W. M. M. Peeters, Gabriel E. Jacobs

Publikováno v: Journal of Psychopharmacology, 25, 353-60
Journal of Psychopharmacology, 25(3), 353-360
Journal of Psychopharmacology, 25, 3, pp. 353-60

Arginine-vasopressin (AVP) is a physiological co-activator of the hypothalamus–pituitary–adrenal (HPA) axis, together with corticotrophin releasing hormone (CRH). A synthetic analogue of AVP, desmopressin (dDAVP), is often used as a pharmacologic

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::974bef2b4785db0ba8c82ddf6cdafab7
https://doi.org/10.1177/0269881109358203

Zobrazit plný text záznamu

A pharmacological tool to assess vasopressinergic co-activation of the hypothalamus–pituitary–adrenal axis more integrally in healthy volunteers

Autor: J. van Pelt, Gabriel E. Jacobs, P A M Peeters, J.M.A. van Gerven, Bernard W. M. M. Peeters, Gé S.F. Ruigt, J Elassaiss-Schaap, E.G.J. Hulskotte, ML de Kam

Publikováno v: Journal of Psychopharmacology, 25(3), 361-369
Journal of Psychopharmacology, 25, 361-369
Journal of Psychopharmacology, 25, 3, pp. 361-369

Pharmacological function tests consisting of 100 µg hCRH (corticorelin) and 10 µg dDAVP (desmopressin) mimic endogenous hypothalamus–pituitary–adrenal (HPA) axis activation. However, physiological CRH concentrations preclude informative vasopre

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c919822d7542a12f58a6a4d890d27490
https://doi.org/10.1177/0269881109358205

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Vyhledávací nástroje:

Upřesnit hledání